Dr Beth Ann Brindley, MD | |
32969 6th Ave, Gobles, MI 49055-9003 | |
(269) 312-2691 | |
Not Available |
Full Name | Dr Beth Ann Brindley |
---|---|
Gender | Female |
Speciality | Obstetrics & Gynecology |
Location | 32969 6th Ave, Gobles, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902133317 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 4301048059 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Beth Ann Brindley, MD 32969 6th Ave, Gobles, MI 49055-9003 Ph: (269) 312-2691 | Dr Beth Ann Brindley, MD 32969 6th Ave, Gobles, MI 49055-9003 Ph: (269) 312-2691 |
News Archive
Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.
Surprising new statistics reveal that 41% of the British population are oblivious to the role that diet plays in the development of cancer - and even those with a family history of the disease are failing to consume potentially "cancer-preventing" compounds in their daily diet.
Neuralstem, Inc. today announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled "Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions," number 11/281,640.
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.
› Verified 3 days ago